The Role of Azithromycin in Patients with Cystic Fibrosis

Paediatric Respiratory Reviews

Volumn 11, Issue 2, 2010, Pages 108-114

  Yousef, Abdullah A ^a,b   Jaffe, Adam ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b KING FAISAL UNIVERSITY   (Saudi Arabia)

Author keywords

Azithromycin; Cystic fibrosis; Inflammation; Macrolides

Indexed keywords

ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; AZITHROMYCIN; CLARITHROMYCIN; ERYTHROMYCIN; JOSAMYCIN; MACROLIDE; PLACEBO; PREDNISONE; ROXITHROMYCIN; SPIRAMYCIN; TROLEANDOMYCIN;

ABDOMINAL PAIN; ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BRONCHIOLITIS; CLINICAL TRIAL; CYSTIC FIBROSIS; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG COMPETITION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG PENETRATION; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; EAR NOSE THROAT DISEASE; GASTROINTESTINAL SYMPTOM; HEARING LOSS; HUMAN; IMMUNOMODULATION; LIVER DYSFUNCTION; LOW DRUG DOSE; NAUSEA; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; TINNITUS; UNSPECIFIED SIDE EFFECT; URTICARIA; VOMITING; WHEEZING;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CYSTIC FIBROSIS; HUMANS;

EID: 77952236405     PISSN: 15260542     EISSN: 15260550     Source Type: Journal    
DOI: 10.1016/j.prrv.2009.12.003     Document Type: Review

References (57)

1. Wariwck W.J. Center directors remember: Minnesota. Cystic Fibrosis in the 20th Century 2001, 315-334. Cleveland, OH, AM Publishing Ltd. C.F. Doershuk (Ed.).
2. Kaplan M.A., Goldin M. The use of triacetyloleandomycin in chronic infectious asthma. Antibiot Annu 1958, 6:273-276.
3. Tredaniel J., Zalcman G., Gerber F., d'Agay M.F., Capron F., Frija J., et al. Diffuse panbronchiolitis: efficacy of low-dose erythromycin. Respir Med 1993, 87:229-230.
4. Nagai H., Shishido H., Yoneda R., Yamaguchi E., Tamura A., Kurashima A. Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis. Respiration 1991, 58:145-149.
5. Jaffe A., Francis J., Rosenthal M., Bush A. Long-term azithromycin may improve lung function in children with cystic fibrosis. Lancet 1998, 351:420.
6. Stamler D.A., Edelstein M.A., Edelstein P.H. Azithromycin pharmacokinetics and intracellular concentrations in Legionella pneumophila-infected and uninfected guinea pigs and their alveolar macrophages. Antimicrob Agents Chemother 1994, 38:217-222.
7. Kirst H.A., Sides G.D. New directions for macrolide antibiotics: pharmacokinetics and clinical efficacy. Antimicrob Agents Chemother 1989, 33:1419-1422.
8. Hoiby N. Diffuse panbronchiolitis and cystic fibrosis: East meets West. Thorax 1994, 49:531-532.
9. Jaffe A., Bush A. Anti-inflammatory effects of macrolides in lung disease. Pediatr Pulmonol 2001, 31:464-473.
10. FitzSimmons S.C. The changing epidemiology of cystic fibrosis. J Pediatr 1993, 122:1-9.
11. Jaffe A., Bush A. Macrolides in cystic fibrosis. Antibiotics as anti-inflammatory and immunomodulatory agents 2005, Birkhäuser Publishing, Basil.
12. Khan T.Z., Wagener J.S., Bost T., Martinez J., Accurso F.J., Riches D.W. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995, 151:1075-1082.
13. Henke M.O., Renner A., Huber R.M., Seeds M.C., Rubin B.K. MUC5AC and MUC5B Mucins Are Decreased in Cystic Fibrosis Airway Secretions. Am J Respir Cell Mol Biol 2004, 31:86-91.
14. Ramphal R., Arora S.K. Recognition of mucin components by Pseudomonas aeruginosa. Glycoconj J 2001, 18:709-713.
15. Sakito O., Kadota J., Kohno S., Abe K., Shirai R., Hara K. Interleukin 1 beta, tumor necrosis factor alpha, and interleukin 8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: a potential mechanism of macrolide therapy. Respiration 1996, 63:42-48.
16. Khair O.A., Devalia J.L., Abdelaziz M.M., Sapsford R.J., Davies R.J. Effect of erythromycin on Haemophilus influenzae endotoxin-induced release of IL-6, IL-8 and sICAM-1 by cultured human bronchial epithelial cells. Eur Respir J 1995, 8:1451-1457.
17. Suzuki H., Shimomura A., Ikeda K., Furukawa M., Oshima T., Takasaka T. Inhibitory effect of macrolides on interleukin-8 secretion from cultured human nasal epithelial cells. Laryngoscope 1997, 107(12 Pt 1):1661-1666.
18. Suzaki H., Asano K., Ohki S., Kanai K., Mizutani T., Hisamitsu T. Suppressive activity of a macrolide antibiotic, roxithromycin, on pro-inflammatory cytokine production in vitro and in vivo. Mediators Inflamm 1999, 8:199-204.
19. Kawasaki S., Takizawa H., Ohtoshi T., Takeuchi N., Kohyama T., Nakamura H., et al. Roxithromycin inhibits cytokine production by and neutrophil attachment to human bronchial epithelial cells in vitro. Antimicrob Agents Chemother 1998, 42:1499-1502.
20. Desaki M., Takizawa H., Ohtoshi T., Kasama T., Kobayashi K., Sunazuka T., et al. Erythromycin suppresses nuclear factor-kappaB and activator protein-1 activation in human bronchial epithelial cells. Biochem Biophys Res Commun 2000, 267:124-128.
21. Li Y., Azuma A., Takahashi S., Usuki J., Matsuda K., Aoyama A., et al. Fourteen-membered ring macrolides inhibit vascular cell adhesion molecule 1 messenger RNA induction and leukocyte migration: role in preventing lung injury and fibrosis in bleomycin-challenged mice. Chest 2002, 122:2137-2145.
22. Uriarte S.M., Molestina R.E., Miller R.D., Bernabo J., Farinati A., Eiguchi K., et al. Effect of macrolide antibiotics on human endothelial cells activated by Chlamydia pneumoniae infection and tumor necrosis factor-alpha. J Infect Dis 2002, 185:1631-1636.
23. Culic O., Erakovic V., Cepelak I., Barisic K., Brajsa K., Ferencic Z., et al. Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. Eur J Pharmacol 2002, 450:277-289.
24. Labro M.T., el Benna J., Babin-Chevaye C. Comparison of the in-vitro effect of several macrolides on the oxidative burst of human neutrophils. J Antimicrob Chemother 1989, 24:561-572.
25. Aoshiba K., Nagai A., Konno K. Erythromycin shortens neutrophil survival by accelerating apoptosis. Antimicrob Agents Chemother 1995, 39:872-877.
26. Baumann U., Fischer J.J., Gudowius P., Lingner M., Herrmann S., Tummler B., et al. Buccal adherence of Pseudomonas aeruginosa in patients with cystic fibrosis under long-term therapy with azithromycin. Infection 2001, 29:7-11.
27. Kobayashi H. Biofilm disease: its clinical manifestation and therapeutic possibilities of macrolides. Am J Med 1995, 99:26S-30S.
28. Mitsuya Y., Kawai S., Kobayashi H. Influence of macrolides on guanosine diphospho-D-mannose dehydrogenase activity in Pseudomonas biofilm. J Infect Chemother 2000, 6:45-50.
29. Nalca Y., Jansch L., Bredenbruch F., Geffers R., Buer J., Haussler S. Quorum-sensing antagonistic activities of azithromycin in Pseudomonas aeruginosa PAO1: a global approach. Antimicrob Agents Chemother 2006, 50:1680-1688.
30. Skindersoe M.E., Alhede M., Phipps R., Yang L., Jensen P.O., Rasmussen T.B., et al. Effects of antibiotics on quorum sensing in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2008, 52:3648-3663.
31. Tateda K., Comte R., Pechere J.C., Kohler T., Yamaguchi K., Van Delden C. Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2001, 45:1930-1933.
32. Tateda K., Ishii Y., Matsumoto T., Furuya N., Nagashima M., Matsunaga T., et al. Direct evidence for antipseudomonal activity of macrolides: exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin. Antimicrob Agents Chemother 1996, 40:2271-2275.
33. Molinari G., Guzman C.A., Pesce A., Schito G.C. Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics. J Antimicrob Chemother 1993, 31:681-688.
34. Ichimiya T., Takeoka K., Hiramatsu K., Hirai K., Yamasaki T., Nasu M. The influence of azithromycin on the biofilm formation of Pseudomonas aeruginosa in vitro. Chemotherapy 1996, 42:186-191.
35. Tagaya E., Tamaoki J., Kondo M., Nagai A. Effect of a short course of clarithromycin therapy on sputum production in patients with chronic airway hypersecretion. Chest 2002, 122:213-218.
36. Tamaoki J., Isono K., Sakai N., Kanemura T., Konno K. Erythromycin inhibits Cl secretion across canine tracheal epithelial cells. Eur Respir J 1992, 5:234-238.
37. Oliynyk I., Varelogianni G., Schalling M., Asplund M.S., Roomans G.M., Johannesson M. Azithromycin increases chloride efflux from cystic fibrosis airway epithelial cells. Exp Lung Res 2009, 35:210-221.
38. Mitsuyama T., Hidaka K., Furuno T., Hara N. Neutrophil-induced endothelial cell damage: inhibition by a 14-membered ring macrolide through the action of nitric oxide. Int Arch Allergy Immunol 1997, 114:111-115.
39. Takizawa H., Desaki M., Ohtoshi T., Kawasaki S., Kohyama T., Sato M., et al. Erythromycin and clarithromycin attenuate cytokine-induced endothelin-1 expression in human bronchial epithelial cells. Eur Respir J 1998, 12:57-63.
40. Yatsunami J., Fukuno Y., Nagata M., Tsuruta N., Aoki S., Tominaga M., et al. Roxithromycin and clarithromycin, 14-membered ring macrolides, potentiate the antitumor activity of cytotoxic agents against mouse B16 melanoma cells. Cancer Lett 1999, 147:17-24.
41. Feldman C., Anderson R., Theron A., Mokgobu I., Cole P.J., Wilson R. The effects of ketolides on bioactive phospholipid-induced injury to human respiratory epithelium in vitro. Eur Respir J 1999, 13:1022-1028.
42. Bergamini G., Cigana C., Sorio C., Della P.M., Pompella A., Corti A., et al. Effects of Azithromycin (AZM) on Glutathione-S-Transferases (GST)s in Cystic Fibrosis Airway Cells. Am J Respir Cell Mol Biol 2008.
43. Hansen C.R., Pressler T., Koch C., Hoiby N. Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study. J Cyst Fibros 2005, 4:35-40.
44. Hansen C.R., Pressler T., Hoiby N., Johansen H.K. Long-term, low-dose azithromycin treatment reduces the incidence but increases macrolide resistance in Staphylococcus aureus in Danish CF patients. J Cyst Fibros 2009, 8:58-62.
45. Pirzada O.M., McGaw J., Taylor C.J., Everard M.L. Improved lung function and body mass index associated with long-term use of Macrolide antibiotics. J Cyst Fibros 2003, 2:69-71.
46. Southern KW, Barker PM, Solis A. Macrolide antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2004;(2):CD002203.
47. Tramper-Stranders G.A., Wolfs T.F., Fleer A., Kimpen J.L., van der Ent C.K. Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function. Pediatr Infect Dis J 2007, 26:8-12.
48. Wolter J., Seeney S., Bell S., Bowler S., Masel P., McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002, 57:212-216.
49. Equi A., Balfour-Lynn I.M., Bush A., Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 2002, 360:978-984.
50. Saiman L., Marshall B.C., Mayer-Hamblett N., Burns J.L., Quittner A.L., Cibene D.A., et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003, 290:1749-1756.
51. Clement A., Tamalet A., Leroux E., Ravilly S., Fauroux B., Jais J.P. Long term effects of azithromycin in patients with cystic fibrosis: A double blind, placebo controlled trial. Thorax 2006, 61:895-902.
52. Steinkamp G., Schmitt-Grohe S., Doring G., Staab D., Pfrunder D., Beck G., et al. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection. Respir Med 2008, 102:1643-1653.
53. Saiman L., Mayer-Hamblett N., Campbell P., Marshall B.C. Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. Am J Respir Crit Care Med 2005, 172:1008-1012.
54. Ordonez C.L., Stulbarg M., Grundland H., Liu J.T., Boushey H.A. Effect of clarithromycin on airway obstruction and inflammatory markers in induced sputum in cystic fibrosis: a pilot study. Pediatr Pulmonol 2001, 32:29-37.
55. McCormack J., Bell S., Senini S., Walmsley K., Patel K., Wainwright C., et al. Daily versus weekly azithromycin in cystic fibrosis patients. Eur Respir J 2007, 30:487-495.
56. Florescu D.F., Murphy P.J., Kalil A.C. Effects of prolonged use of azithromycin in patients with cystic fibrosis: A meta-analysis. Pulm Pharmacol Ther 2009.
57. Griffith D.E., Aksamit T., Brown-Elliott B.A., Catanzaro A., Daley C., Gordin F., et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007, 175:367-416.